HepaRegeniX develops a new and unique therapeutic concept to combat multiple liver diseases.
Find out more
Science
HepaRegeniX aims at curing liver diseases by reversing the disease path through liver regeneration. Along this path, the company is actively developing novel therapies for the treatment of both acute and chronic liver diseases.
Latest Press Releases
HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure
U.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection Tuebingen, Germany, August 26, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)Continue reading "HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure"
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
Tuebingen, Germany, May 13, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical data for the lead candidate darizmetinib (formerly HRX215) has been selected for a late-breaking oral presentation at the European Association for the Study of the Liver (EASL)Continue reading "HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026"